Effect of Curcumin on Metabolism of Lipids in Streptozotocin induced Diabetic and normal Rats

Najafian, Mahmood
July 2014
Advances in Environmental Biology;Jul2014, Vol. 8 Issue 12, p170
Academic Journal
Background: Diabetes mellitus is one of the most common endocrine disorders characterized by hyperglycemia, hypercholesterolemia, and hypertriglyceridemia. A prudent strategy for preventing cardiovascular complications in patients with diabetes is treating dyslipidemia with lipid-lowering agents. Objective: We aimed to examine the effect of curcumin on metabolism of lipids in diabetic and normal rats. Method: For this purpose in this research, doses of curcumin (0, 10, 20, 40 and 80 mg/kg-b.w) were given to diabetic and normal rats and blood sample of them were analyzed. Result: In diabetic group as compared to normal control group, the blood cholesterol, triglycerides, very low density lipoprotein-cholesterol (VLDL-C) and low density lipoprotein-cholesterol (LDL-C) levels, the water intake and urine volume were significantly increased while high density lipoprotein-cholesterol (HDL-C) was significantly decreased. In both groups diabetic and normal groups treated with curcumin; the levels of cholesterol, triglycerides, VLDL-C, and LDL-C decreased however only the level of HDL-C increased in diabetic groups. In diabetic groups treated with curcumin, the levels of water intake and urine volume decreased but in normal groups these changes were not significant. Conclusion: It may be concluded that curcumin as a lipid-lowering agents has beneficial effects in the treatment of diabetes and related disorders such as dyslipidemia.


Related Articles

  • Gene Polymorphisms of FABP2, ADIPOQ and ANP and Risk of Hypertriglyceridemia and Metabolic Syndrome in Afro-Caribbeans. Larifla, Laurent; Rambhojan, Christine; Joannes, Marie-Odile; Maimaitiming-Madani, Suliya; Donnet, Jean-Paul; Marianne-Pépin, Thérèse; Chout, Roger; Roussel, Ronan; Foucan, Lydia // PLoS ONE;9/29/2016, Vol. 11 Issue 9, p1 

    Objectives: The metabolic syndrome (MetS) is a cluster of metabolic abnormalities and cardiovascular risk factors that are highly heritable and polygenic. We investigated the association of allelic variants of three candidate genes, rs1799883-FABP2, rs1501299-ADIPOQ and rs5065-ANP with MetS and...

  • Lipid profile in type 2 diabetic and hypertensive population in Western Algeria. Gormat, N. Brixi; Benmansour, F.; Hammas, A. // Annals of Biological Research;2011, Vol. 2 Issue 4, p447 

    Dyslipidemia in diabetics are as high blood pressure to take very seriously, given the significant increase in cardiovascular risks they pose to patients. Anomalies of lipoprotein metabolism are of major importance because of the risks atherogenic increased in diabetic patients. [4, 11] In this...

  • Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial. Arbel, Yaron; Klempfner, Robert; Erez, Aharon; Goldenberg, Ilan; Benzekry, Sagit; Shlomo, Nir; Fisman, Enrique Z.; Tenenbaum, Alexander // Cardiovascular Diabetology;1/22/2016, Vol. 15, p1 

    Background: Recent data support the renewed interest in hypertriglyceridemia as a possible important therapeutic target for cardiovascular risk reduction. This study was designed to address the question of all-cause mortality during extended follow-up of the BIP trial in patients stratified by...

  • Guideline-Driven Intervention on SCI-Associated Dyslipidemia, Metabolic Syndrome, and Glucose Intolerance Using Pharmacological Agents. Ronald Goldberg // Topics in Spinal Cord Injury Rehabilitation;Jan2009, Vol. 14 Issue 3, p46 

    This review summarizes current thinking and evidence-based recommendations for pharmacotherapy in the treatment of dyslipidemia, metabolic syndrome, and glucose intolerance as a basis for their application to individuals with a spinal cord injury (SCI). Although the evidence that subjects with...

  • Get more aggressive with treatments to cut heart risk. Gebhart, Fred // Drug Topics;10/6/2003 Supplement, Vol. 147 Issue 19, p13s 

    Reports on the importance of aggressive diabetes treatment to the prevention of cardiovascular complications. Research on the effectiveness of multiple treatments; Implications for pharmacy-based diabetes treatment clinics.

  • Hypertriglyceridemia: A dangerous family affair. Pinkowish, Mary Desmond // Patient Care for the Nurse Practitioner;Sep2000, Vol. 3 Issue 9, p12 

    Presents information on a study which clarified the impact of hypertriglyceridemia on cardiovascular disease risk. Methodology; Findings of the study; Preventive strategy in patients from familial combined hyperlipidemia or familial hypertriglyceridemia.

  • Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers. Chiquette, Elaine; Toth, Peter P.; Ramirez, Gilbert; Cobble, Michael; Chilton, Robert // Vascular Health & Risk Management;2012 Part 2, Vol. 8, p621 

    Background: Dyslipidemia and type 2 diabetes are two of the most significant risk factors for the development of cardiovascular disease. Measurement of lipoprotein subclasses provides important information about derangements in lipid metabolism and helps refine cardiovascular risk assessment....

  • Management of Dyslipidemia for Cardiovascular Disease Risk Reduction. Downs, John R.; O'Malley, Patrick C.; O'Malley, Patrick G // Annals of Internal Medicine;4/5/2016, Vol. 164 Issue 7, p509 

    A response from the authors of the article "Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline" in the 2015 issue is presented.

  • Lipid metabolism and the risk factors of cardiovascular disease: implication of dietary omega-3 polyunsaturated fatty acids. Balogun, Kayode A. // Applied Physiology, Nutrition & Metabolism;Feb2016, Vol. 41 Issue 2, p223 

    Cardiovascular disease (CVD) is a complicated and multifarious disease, and is the number one cause of mortality worldwide. The pathogenesis of CVD is attributed to the interaction between genetics and environment. There are numerous data that support the cardioprotective properties of omega (...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics